Immunology Section, Department of Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
PLoS One. 2010 Feb 5;5(2):e9095. doi: 10.1371/journal.pone.0009095.
Chronic transplant dysfunction explains the majority of late renal allograft loss and is accompanied by extensive tissue remodeling leading to transplant vasculopathy, glomerulosclerosis and interstitial fibrosis. Matrix proteoglycans mediate cell-cell and cell-matrix interactions and play key roles in tissue remodeling. The aim of this study was to characterize differential heparan sulfate proteoglycan and chondroitin sulfate proteoglycan expression in transplant vasculopathy, glomerulosclerosis and interstitial fibrosis in renal allografts with chronic transplant dysfunction.
Renal allografts were transplanted in the Dark Agouti-to-Wistar Furth rat strain combination. Dark Agouti-to-Dark Agouti isografts and non-transplanted Dark Agouti kidneys served as controls. Allograft and isograft recipients were sacrificed 66 and 81 days (mean) after transplantation, respectively. Heparan sulfate proteoglycan (collXVIII, perlecan and agrin) and chondroitin sulfate proteoglycan (versican) expression, as well as CD31 and LYVE-1 (vascular and lymphatic endothelium, respectively) expression were (semi-) quantitatively analyzed using immunofluorescence.
Arteries with transplant vasculopathy and sclerotic glomeruli in allografts displayed pronounced neo-expression of collXVIII and perlecan. In contrast, in interstitial fibrosis expression of the chondroitin sulfate proteoglycan versican dominated. In the cortical tubular basement membranes in both iso- and allografts, induction of collXVIII was detected. Allografts presented extensive lymphangiogenesis (p<0.01 compared to isografts and non-transplanted controls), which was associated with induced perlecan expression underneath the lymphatic endothelium (p<0.05 and p<0.01 compared to isografts and non-transplanted controls, respectively). Both the magnitude of lymphangiogenesis and perlecan expression correlated with severity of interstitial fibrosis and impaired graft function.
Our results reveal that changes in the extent of expression and the type of proteoglycans being expressed are tightly associated with tissue remodeling after renal transplantation. Therefore, proteoglycans might be potential targets for clinical intervention in renal chronic transplant dysfunction.
慢性移植功能障碍解释了大多数晚期肾移植丢失的原因,并伴有广泛的组织重塑,导致移植血管病、肾小球硬化和间质纤维化。基质蛋白聚糖介导细胞-细胞和细胞-基质相互作用,并在组织重塑中发挥关键作用。本研究的目的是描述在伴有慢性移植功能障碍的肾移植中,移植血管病、肾小球硬化和间质纤维化中差异表达的硫酸乙酰肝素蛋白聚糖和硫酸软骨素蛋白聚糖。
将肾移植在 Dark Agouti-to-Wistar Furth 大鼠品系组合中进行。Dark Agouti-to-Dark Agouti 同种异体移植和未移植的 Dark Agouti 肾脏作为对照。同种异体和同种异体移植受者分别在移植后 66 和 81 天(平均值)处死。使用免疫荧光(semi-)定量分析硫酸乙酰肝素蛋白聚糖(collXVIII、perlecan 和 agrin)和硫酸软骨素蛋白聚糖(versican)的表达,以及 CD31 和 LYVE-1(分别为血管和淋巴管内皮细胞)的表达。
移植血管病和同种异体移植肾小球硬化的动脉显示出明显的 collXVIII 和 perlecan 的新生表达。相比之下,在间质纤维化中,chondroitin sulfate proteoglycan versican 的表达占主导地位。在同种异体和同种异体移植的皮质管状基底膜中,检测到 collXVIII 的诱导。同种异体移植存在广泛的淋巴管生成(与同种异体和未移植对照相比,p<0.01),这与淋巴管内皮下方诱导的 perlecan 表达相关(与同种异体和未移植对照相比,p<0.05 和 p<0.01)。淋巴管生成的程度和 perlecan 的表达与间质纤维化和移植肾功能受损的严重程度相关。
我们的结果表明,表达范围和蛋白聚糖类型的变化与肾移植后的组织重塑密切相关。因此,蛋白聚糖可能是慢性移植肾功能障碍的临床干预的潜在靶点。